SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors

A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs

(2022) Zezhong Liu et al.   CELL RESEARCH

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

(2022) Shuai Xia et al.   CELL RESEARCH

Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity

(2022) Bo Meng et al.   NATURE

A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life

(2022) Qianyu Duan et al.   Viruses-Basel

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

(2022) Yunlong Cao et al.   NATURE

Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa

(2022) Houriiyah Tegally et al.   NATURE MEDICINE

Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2

(2022) Xiaoyu Sun et al.   Nature Microbiology

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant

(2022) Akatsuki Saito et al.   Cell Host & Microbe

The outbreak of SARS‐CoV‐2 Omicron lineages, immune escape, and vaccine effectivity

(2022) Yongbing Zhou et al.   JOURNAL OF MEDICAL VIROLOGY

Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies

(2022) Daniel J Sheward et al.   LANCET INFECTIOUS DISEASES

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6

(2022) Nicole P. Hachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2

(2022) Bingjie Hu et al.   Emerging Microbes & Infections

A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein

(2022) Songyi Xue et al.   Cell Discovery

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides

(2022) Yuanmei Zhu et al.   ANTIVIRAL RESEARCH

Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2

(2021) Yinghui Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of a High-Frequency Intrahost SARS-CoV-2 Spike Variant with Enhanced Cytopathic and Fusogenic Effects

(2021) Lynda Rocheleau et al.   mBio

Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation

(2021) Akatsuki Saito et al.   NATURE

Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha)

(2021) Shuai Xia et al.   Cell Discovery

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

(2020) Shuai Xia et al.   Cellular & Molecular Immunology

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

(2020) Shuai Xia et al.   CELL RESEARCH

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

(2019) Shuai Xia et al.   Science Advances

Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor

(2014) Lu Lu et al.   Nature Communications